Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | pyruvate kinase 1 | 0.0027 | 0.1946 | 1 |
Onchocerca volvulus | Pyruvate kinase homolog | 0.0027 | 0.1946 | 1 |
Loa Loa (eye worm) | pyruvate kinase | 0.0027 | 0.1946 | 1 |
Brugia malayi | Pyruvate kinase, alpha/beta domain containing protein | 0.0008 | 0.0053 | 0.027 |
Schistosoma mansoni | pyruvate kinase | 0.0027 | 0.1946 | 0.1946 |
Echinococcus multilocularis | pyruvate kinase | 0.0021 | 0.1374 | 0.1432 |
Giardia lamblia | Pyruvate kinase | 0.0027 | 0.1946 | 1 |
Echinococcus multilocularis | pyruvate kinase | 0.0014 | 0.0625 | 0.0651 |
Echinococcus granulosus | transcription factor btf3 | 0.0026 | 0.1867 | 0.1867 |
Plasmodium vivax | pyruvate kinase, putative | 0.0027 | 0.1946 | 1 |
Loa Loa (eye worm) | pyruvate kinase | 0.0027 | 0.1946 | 1 |
Brugia malayi | Pyruvate kinase, muscle isozyme | 0.0027 | 0.1946 | 1 |
Trypanosoma brucei | pyruvate kinase 1, putative | 0.0027 | 0.1946 | 1 |
Trichomonas vaginalis | pyruvate kinase, putative | 0.0027 | 0.1946 | 1 |
Mycobacterium ulcerans | pyruvate kinase | 0.0027 | 0.1946 | 0.5 |
Brugia malayi | beta-NAC-like protein | 0.0026 | 0.1867 | 0.9595 |
Echinococcus multilocularis | pyruvate kinase | 0.0027 | 0.1946 | 0.2029 |
Echinococcus granulosus | pyruvate kinase | 0.0027 | 0.1946 | 0.1946 |
Onchocerca volvulus | Pyruvate kinase homolog | 0.0027 | 0.1946 | 1 |
Echinococcus multilocularis | pyruvate kinase | 0.0027 | 0.1946 | 0.2029 |
Loa Loa (eye worm) | hypothetical protein | 0.0019 | 0.1125 | 0.5779 |
Echinococcus multilocularis | pyruvate kinase | 0.0014 | 0.0625 | 0.0651 |
Echinococcus multilocularis | retinoic acid receptor rxr beta a retinoic acid receptor rxr alpha a retinoic acid receptor rxr alpha | 0.0102 | 0.9594 | 1 |
Echinococcus granulosus | pyruvate kinase | 0.0027 | 0.1946 | 0.1946 |
Plasmodium vivax | basic transcription factor 3b, putative | 0.0026 | 0.1867 | 0.9403 |
Entamoeba histolytica | hypothetical protein | 0.0026 | 0.1867 | 1 |
Echinococcus granulosus | pyruvate kinase | 0.0014 | 0.0625 | 0.0625 |
Plasmodium falciparum | pyruvate kinase | 0.0027 | 0.1946 | 1 |
Trypanosoma cruzi | pyruvate kinase 2, putative | 0.0027 | 0.1946 | 1 |
Schistosoma mansoni | pyruvate kinase | 0.0014 | 0.0625 | 0.0625 |
Schistosoma mansoni | transcription factor btf3 | 0.0026 | 0.1867 | 0.1867 |
Echinococcus multilocularis | pyruvate kinase | 0.0014 | 0.0625 | 0.0651 |
Loa Loa (eye worm) | ICD-1 protein | 0.0026 | 0.1867 | 0.9595 |
Trypanosoma cruzi | pyruvate kinase 2, putative | 0.0027 | 0.1946 | 1 |
Trichomonas vaginalis | pyruvate kinase, putative | 0.0027 | 0.1946 | 1 |
Mycobacterium leprae | Probable pyruvate kinase PykA | 0.0027 | 0.1946 | 0.5 |
Toxoplasma gondii | pyruvate kinase PyK1 | 0.0027 | 0.1946 | 1 |
Schistosoma mansoni | retinoic acid receptor RXR | 0.0106 | 1 | 1 |
Chlamydia trachomatis | pyruvate kinase | 0.0027 | 0.1946 | 0.5 |
Brugia malayi | Pyruvate kinase, M2 isozyme | 0.0027 | 0.1946 | 1 |
Plasmodium falciparum | basic transcription factor 3b, putative | 0.0026 | 0.1867 | 0.9403 |
Toxoplasma gondii | NAC domain-containing protein | 0.0026 | 0.1867 | 0.9403 |
Entamoeba histolytica | transcription factor BTF3, putative | 0.0026 | 0.1867 | 1 |
Loa Loa (eye worm) | pyruvate kinase-PB | 0.0019 | 0.1125 | 0.5779 |
Leishmania major | pyruvate kinase | 0.0027 | 0.1946 | 1 |
Echinococcus multilocularis | transcription factor btf3 | 0.0026 | 0.1867 | 0.1946 |
Echinococcus granulosus | pyruvate kinase | 0.0014 | 0.0625 | 0.0625 |
Loa Loa (eye worm) | hypothetical protein | 0.0027 | 0.1946 | 1 |
Leishmania major | pyruvate kinase | 0.0027 | 0.1946 | 1 |
Schistosoma mansoni | pyruvate kinase | 0.0027 | 0.1946 | 0.1946 |
Mycobacterium tuberculosis | Probable pyruvate kinase PykA | 0.0027 | 0.1946 | 0.5 |
Loa Loa (eye worm) | pyruvate kinase | 0.0027 | 0.1946 | 1 |
Onchocerca volvulus | Pyruvate kinase homolog | 0.0027 | 0.1946 | 1 |
Echinococcus granulosus | pyruvate kinase | 0.0014 | 0.0625 | 0.0625 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.